Comparing antigenicity and immunogenicity of engineered gp120. - Wikidata - wikimedia - TriplyDB

Comparing antigenicity and immunogenicity of engineered gp120.

Comparing antigenicity and immunogenicity of engineered gp120.

http://www.wikidata.org/entity/Q33984309

about

Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein Rapid profiling of the antigen regions recognized by serum antibodies using massively parallel sequencing of antigen-specific libraries Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology Rational antibody-based HIV-1 vaccine design: current approaches and future directions Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Structure-based vaccine design in HIV: blind men and the elephant?Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.Limitations to the structure-based design of HIV-1 vaccine immunogens.

P2860

Q21558777-59385C0B-84C3-4DE4-98F6-6EFB151ED46A Q27489000-77A70159-3B18-4125-A062-F43D0C1E094A Q28732438-13F3B2C3-8C58-4682-A289-B6BD50C50E7A Q29048193-6C0A6902-7C20-484A-9BBB-DAFFEEFDE4D6 Q30379200-BE2EFBE7-73D8-4895-B4F0-AB8FB09C1FCA Q30418340-E38D7F64-94B1-4AEF-9A33-884EEC1E60DC Q30843874-D17B9312-93A3-497C-A3E2-6FB97D770D8C Q33373664-44DA2097-6951-482B-BED2-06339BB947F3 Q33688229-6DA6D961-25DB-40EC-B533-684B5B208AFE Q33937285-262CD65D-CF46-4942-8657-6F7204722787 Q34094476-BD1823EB-193D-408F-8EF7-935F2339626D Q34204047-128AFE13-DA07-4151-BA4F-130E6DA462F4 Q34480254-99CD4121-5128-481D-A8FB-231F8552DD0B Q34539819-E79C656D-40D2-48E2-B420-C615317F7B95 Q34583767-043BAFFD-68DF-431B-AA18-A706B0DA0CFF Q34610959-2C701A31-36BA-45E9-AFD8-F579532D2235 Q34987048-D4BAFDC9-ED3C-4100-A4DD-03596243B8B2 Q35024202-42C33CFF-2C7B-4416-AB7F-94EB00E6E565 Q35122067-5E65BB3C-E298-4A8C-8789-834BBFF14258 Q35196671-32166977-AED7-4817-8E42-9DC7CD7D5DA6 Q35580892-79DF7430-79F7-4923-8216-09D3667F3454 Q35785338-EC78A247-859F-4FB7-BAA4-785F1C59575C Q35826306-5018B5C9-B225-4622-B22A-A6FC7D8E36D2 Q35857221-53842938-B5A8-4BD9-9142-99771584DC28 Q35857631-2B1F1000-C635-4667-BEA0-77550B84274D Q36079874-C9FC406D-228B-497B-AD19-16CBEAEB780E Q36149102-B1FBAAE2-7482-4853-B0F2-7FFCCC42E24B Q36497712-26199B2A-294C-48E6-8A19-7F081B6DB08A Q36600380-E7647031-46FD-41AD-B663-FEF2482D84B0 Q36742228-BE442105-FA60-4892-A2B1-8B9287087818 Q36804634-05289449-E56A-472E-BBEE-95E81F124CA0 Q36827348-68014CF6-8F64-441C-AAF4-AC3E43671D4C Q36931790-E1DD32D3-B6F1-4970-856D-68D8F40C12B5 Q37033291-095BD3C6-D565-469F-81FE-320FBF76A01C Q37069430-654F90A2-1DF0-4AB7-9BDC-09508EDB2FD0 Q37072702-3D90B261-E069-42FD-BB36-419A5690DEFC Q37192185-B7BC146A-1E2F-4BB7-B28F-BCB8F3D12D0B Q37250899-AD6C6D3F-853B-4592-A464-783BE90633C3 Q37376557-99471159-1DE7-44B7-9DDE-3C713B1BEE9A Q37910841-40C5EADE-5081-45F9-A784-897E56B97DDF

P2860

Comparing antigenicity and immunogenicity of engineered gp120.

http://www.wikidata.org/entity/Q33984309

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Comparing antigenicity and immunogenicity of engineered gp120.

@ast

Comparing antigenicity and immunogenicity of engineered gp120.

@en

type

label

Comparing antigenicity and immunogenicity of engineered gp120.

@ast

Comparing antigenicity and immunogenicity of engineered gp120.

@en

prefLabel

Comparing antigenicity and immunogenicity of engineered gp120.

@ast

Comparing antigenicity and immunogenicity of engineered gp120.

@en

P1433

Q33984309-83139A67-D12E-48B8-98BB-5D9FE461AE34

P1476

Q33984309-D644105A-E9CC-40BC-BDB4-E928C162F5C8

P2093

Q33984309-1DF088F7-0F5B-423D-9FA1-42A841651A51

Q33984309-807E7F93-EA6E-4C4E-9963-4A5054C0F3B6

Q33984309-C8E31C9C-013B-43B2-8937-41D99F0F6C9E

Q33984309-D83EA1C9-D527-4882-B052-A6EC95DB9CBE

Q33984309-E0383F72-DC2D-4EE0-9C06-52B7C9D5B72E

Q33984309-F22CBE8A-D86E-4A93-9407-7C74BA68396E

P2860

Q33984309-01F438CB-7BFD-458D-A905-962806B2D7D9

Q33984309-0B4DD6C8-7C3A-4EC6-BC46-EF67FB4A8FD7

Q33984309-1D2DE962-A6C2-48F1-BF53-01ACDB93FE1E

Q33984309-1D9D76FF-3B90-44F5-99DF-75F376CA1C0D

Q33984309-20C6F75C-6A0C-4FD5-A660-77D94A3EE9F5

Q33984309-2A3AE0C4-8520-4CC4-9C71-D3D49CCB474B

Q33984309-31176CF3-D661-4418-B788-2C6ECFE43A3E

Q33984309-336625D6-CB57-42C9-BCC8-CAEA1182E841

Q33984309-3416B0B7-BE66-48E8-BEBB-F6CF895B0668

Q33984309-36C8A780-3502-4F54-9EF6-28AA10FB013B

P304

Q33984309-88774098-4A97-4785-9C62-19CA5EEBFBDE

P31

Q33984309-9E10433A-8DFA-4E05-98B8-4B83309476BF

P356

Q33984309-B29AB68B-9837-48DF-B12D-53455AB55905

P407

Q33984309-A4EFE5FE-DEF6-4EF6-995F-4DF443AD733E

P433

Q33984309-1C8D1D72-5E06-454B-B9CA-90B48B85B16F

P478

Q33984309-B7F92469-1037-4357-9232-F6A71CC25BB3

P577

Q33984309-4A194F7A-116A-41F7-9F0F-3B16CBB37D7E

P5875

Q33984309-1A82573B-0AAA-4DDB-84B9-CBE01262D0E5

P698

Q33984309-302FCA37-4273-453B-BC2A-179A63A05C07

P932

Q33984309-4A49256B-8B00-40B6-BD2A-9D975E770A77

P356

JVI.79.19.12148-12163.2005

P1433

Journal of Virology

P1476

Comparing antigenicity and immunogenicity of engineered gp120.

@en

P2093

Bridget Puffer

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Mansun Law

http://www.w3.org/2001/XMLSchema#string

Ralph Pantophlet

http://www.w3.org/2001/XMLSchema#string

Robert W Doms

http://www.w3.org/2001/XMLSchema#string

Suganya Selvarajah

http://www.w3.org/2001/XMLSchema#string

P2860

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

P304

12148-12163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.79.19.12148-12163.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7603063

http://www.w3.org/2001/XMLSchema#string

P698

16160142

http://www.w3.org/2001/XMLSchema#string

P932

1211546

http://www.w3.org/2001/XMLSchema#string